A detailed history of Cetera Investment Advisers transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Cetera Investment Advisers holds 585,879 shares of BMY stock, worth $33.9 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
585,879
Previous 548,206 6.87%
Holding current value
$33.9 Million
Previous $22.8 Million 33.18%
% of portfolio
0.07%
Previous 0.05%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$39.66 - $51.75 $1.49 Million - $1.95 Million
37,673 Added 6.87%
585,879 $30.3 Million
Q2 2024

Aug 22, 2024

SELL
$40.25 - $52.99 $1.07 Million - $1.4 Million
-26,477 Reduced 4.61%
548,206 $22.8 Million
Q1 2024

May 24, 2024

BUY
$47.98 - $54.4 $23.4 Million - $26.5 Million
487,299 Added 557.65%
574,683 $31.2 Million
Q1 2024

May 14, 2024

SELL
$47.98 - $54.4 $3.42 Million - $3.88 Million
-71,315 Reduced 44.94%
87,384 $4.74 Million
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $952,680 - $1.14 Million
19,651 Added 14.13%
158,699 $8.14 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $1.54 Million - $1.72 Million
-26,605 Reduced 16.06%
139,048 $8.07 Million
Q2 2023

Aug 09, 2023

SELL
$63.71 - $70.74 $630,856 - $700,467
-9,902 Reduced 5.64%
165,653 $10.6 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $530,542 - $601,755
8,074 Added 4.82%
175,555 $12.2 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $4.7 Million - $5.57 Million
68,642 Added 69.45%
167,481 $12 Million
Q3 2022

Nov 10, 2022

SELL
$0.13 - $76.84 $6,268 - $3.7 Million
-48,217 Reduced 32.79%
98,839 $7.03 Million
Q2 2022

Aug 11, 2022

SELL
$72.62 - $79.98 $1.25 Million - $1.38 Million
-17,281 Reduced 10.52%
147,056 $11.3 Million
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $274,200 - $328,791
4,460 Added 2.79%
164,337 $12 Million
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $997,678 - $1.16 Million
18,603 Added 13.17%
159,877 $9.97 Million
Q3 2021

Nov 16, 2021

SELL
$59.17 - $69.31 $698,206 - $817,858
-11,800 Reduced 7.71%
141,274 $8.36 Million
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $415,787 - $452,792
6,716 Added 4.59%
153,074 $10.2 Million
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $786,670 - $884,772
-13,257 Reduced 8.31%
146,358 $9.24 Million
Q4 2020

Feb 17, 2021

BUY
$57.74 - $65.43 $8.13 Million - $9.21 Million
140,830 Added 749.69%
159,615 $9.9 Million
Q3 2020

Nov 13, 2020

SELL
$57.43 - $63.64 $35,089 - $38,884
-611 Reduced 3.15%
18,785 $1.13 Million
Q2 2020

Aug 13, 2020

BUY
$54.82 - $64.09 $21,270 - $24,866
388 Added 2.04%
19,396 $1.14 Million
Q1 2020

May 08, 2020

BUY
$46.4 - $67.43 $16,704 - $24,274
360 Added 1.93%
19,008 $1.06 Million
Q4 2019

Feb 10, 2020

BUY
$49.21 - $64.19 $111,460 - $145,390
2,265 Added 13.83%
18,648 $1.19 Million
Q3 2019

Nov 06, 2019

SELL
$42.77 - $50.71 $43,368 - $51,419
-1,014 Reduced 5.83%
16,383 $834,000
Q2 2019

Aug 12, 2019

SELL
$44.62 - $49.34 $555,563 - $614,332
-12,451 Reduced 41.71%
17,397 $789,000
Q1 2019

May 06, 2019

BUY
$45.12 - $53.8 $11,415 - $13,611
253 Added 0.85%
29,848 $1.43 Million
Q4 2018

Feb 15, 2019

BUY
$48.76 - $63.23 $11,214 - $14,542
230 Added 0.78%
29,595 $1.54 Million
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $159,940 - $180,400
-2,898 Reduced 8.98%
29,365 $1.81 Million
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $98,584 - $122,873
1,951 Added 6.44%
32,263 $1.79 Million
Q1 2018

May 09, 2018

SELL
$59.92 - $68.98 $168,315 - $193,764
-2,809 Reduced 8.48%
30,312 $1.92 Million
Q4 2017

Feb 08, 2018

BUY
$59.94 - $65.35 $49,690 - $54,175
829 Added 2.57%
33,121 $2.03 Million
Q3 2017

Nov 16, 2017

BUY
$55.23 - $63.74 $244,724 - $282,431
4,431 Added 15.9%
32,292 $2.06 Million
Q2 2017

Aug 17, 2017

SELL
N/A
-41,476 Reduced 59.82%
27,861 $1.55 Million
Q2 2017

Aug 14, 2017

BUY
N/A
69,337
69,337 $3.87 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Cetera Investment Advisers Portfolio

Follow Cetera Investment Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cetera Investment Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Cetera Investment Advisers with notifications on news.